|本期目录/Table of Contents|

[1]于艳芳,刘艳红,霍美蓉.纳米递送载体在口服抗肿瘤药物给药系统中的应用[J].生物加工过程,2018,16(05):64-70.[doi:10.3969/j.issn.1672-3678.2018.05.009]
 YU Yanfang,LIU Yanhong,HUO Meirong.Application of nanocarriers for oral delivery of anticancer drugs[J].Chinese Journal of Bioprocess Engineering,2018,16(05):64-70.[doi:10.3969/j.issn.1672-3678.2018.05.009]
点击复制

纳米递送载体在口服抗肿瘤药物给药系统中的应用()
分享到:

《生物加工过程》[ISSN:1672-3678/CN:32-1706/Q]

卷:
16
期数:
2018年05期
页码:
64-70
栏目:
出版日期:
2018-09-29

文章信息/Info

Title:
Application of nanocarriers for oral delivery of anticancer drugs
文章编号:
1672-3678(2018)05-0064-07
作者:
于艳芳1刘艳红2霍美蓉2
1.南京工业大学 生物与制药工程学院,江苏 南京 211800; 2.中国药科大学 药学院,江苏 南京 210009
Author(s):
YU Yanfang1LIU Yanhong2HUO Meirong2
1.College of Biotechnology and Pharmaceutical Engineering,Nanjing Tech University,Nanjing 211800,China; 2.School of Pharmacy,China Pharmaceutical University,Nanjing 210009,China
关键词:
纳米药物递送系统 口服递送 抗癌药物 生理病理屏障 P-糖蛋白 生物材料
分类号:
R318.08
DOI:
10.3969/j.issn.1672-3678.2018.05.009
文献标志码:
A
摘要:
化疗治疗是目前肿瘤治疗的主要手段之一,但大部分化疗药物具有水溶性低、肠道壁通透性差、易受到P-糖蛋白(P-gp)外排的性质,极大限制了其开发为口服制剂。基于纳米技术的药物递送系统在口服抗肿瘤药物的递送中具有独特的优势,表现出良好的应用前景。笔者将深入探讨纳米递送载体在药物口服递送中所面临的生理障碍以及克服生理屏障的方法,并对聚合物胶束、脂质体、纳米粒等纳米体载体在抗肿瘤药物口服递药系统的应用进行了详细的综述。

参考文献/References:

[1] ZHANG H,DOU J,ZHAI Y,et al.Advances in the formulations of non-injection administration of docetaxel[J].J Drug Targeting,2014,22(2):87-94.
[2] KOOLEN S L,BEIJNEN J H,SCHELLENS J H.Intravenous-to-oral switch in anticancer chemotherapy:a focus on docetaxel and paclitaxel[J].Clin Pharm Ther,2010,87(1):126-129.
[3] GRIFFIN B T,GUO J,PRESAS E,et al.Pharmacokinetic,pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs[J].Adv Drug Deliv Rev,2016,106:367-380.
[4] Sohail M F,Rehman M,Sarwar H S,et al.Advancements in the oral delivery of Docetaxel:challenges,current state-of-the-art and future trends.[J].Int J Nanomed,2018,13:3145-3161.
[5] CHOUDHURY H,GORAIN B,TEKADE R K,et al.Safety against nephrotoxicity in paclitaxel treatment:oral nanocarrier as an effective tool in preclinical evaluation with marked in vivo antitumor activity[J].Regul Toxicol pharmacol:2017,91:179-189.
[6] THANKI K,GANGWAL R P,SANGAMWAR A T,et al.Oral delivery of anticancer drugs:challenges and opportunities[J].J Control Release,2013,170(1):15-40.
[7] ARAJO F,DAS NEVES J,MARTINS J P,et al.Functionalized materials for multistage platforms in the oral delivery of biopharmaceuticals[J].Prog Mater Sci,2017,89:306-344.
[8] FUHRMANN K,FUHRMANN G.Recent advances in oral delivery of macromolecular drugs and benefits of polymer conjugation[J].Curr Opin Colloid Interface Sci,2017,31:67-74.
[9] 徐鹏程.纳米技术在口服给药系统中的应用[J].内蒙古科技与经济,2016(10):80.
[10] SHIMIZU K.Development of new liposome targeting strategies for application of disease therapies[J].Yakugaku Zasshi:J Pharm Soc Japan,2017,137(1):43-48.
[11] ADEOYE O,CABRAL-MARQUES H.Cyclodextrin nanosystems in oral drug delivery:a mini review[J].Int J Pharm,2017,531(2):521-531.
[12] FAN W,ZHANG L,LI Y,et al.Recent progress of crosslinking strategies for polymeric micelles with enhanced drug delivery in cancer therapy[J].Curr Med Chem,1969,doi:10.2174/0929867324666171121102255.
[13] REHMAN M,IHSAN A,MADNI A,et al.Solid lipid nanoparticles for thermoresponsive targeting:evidence from spectrophotometry,electrochemical,and cytotoxicity studies[J].Int J Nanomed,2017,12:8325-8336.
[14] SUN J,LIU Y,GE M,et al.A Distinct endocytic mechanism of functionalized-silica nanoparticles in breast cancer stem cells[J].Sci Rep,2017,doi:10.1038/s41598-017-16591-z.
[15] MOHAMMED M A,SYEDA J T M,WASAN K M,et al.An Overview of chitosan nanoparticles and its application in non-parenteral drug delivery[J].Pharmaceutics,2017,doi:10.3390/pharmaceutics9040053.
[16] Kang X,Chen H,Li S,et al.Magnesium lithospermate B loaded PEGylated solid lipid nanoparticles for improved oral bioavailability[J].Colloids Surface B,2017,161:597-605.
[17] MEI L,ZHANG Z,ZHAO L,et al.Pharmaceutical nanotechnology for oral delivery of anticancer drugs[J].Adv Drug Deliv Rev,2013,65(6):880-890.
[18] Jain A K,JAIN S.Advances in oral delivery of anti-cancer prodrugs[J].Expert Opin Drug Deliv,2016,13(12):1759-1775.
[19] GEDAWY A,MARTINEZ J,AL-SALAMI H,et al.Oral insulin delivery:existing barriers and current counter-strategies[J].J Pharm Pharmacol,2017,70(2):197-213.
[20] 杨晖,姚静,周建平.针对胃肠道黏液屏障的口服纳米粒研究进展[J].药学与临床研究,2012,20(4):339-342.
[21] KARLSSON J,WIKMAN A,ARTURSSON P.The mucus layer as a barrier to drug absorption in monolayers of human intestinal epithelial HT29-H goblet cells[J].Int J Pharma,1993,99(2/3):209-218.
[22] Date A A,Hanes J,Ensign L M.Nanoparticles for oral delivery:design,evaluation and state-of-the-art[J].J Control Release,2016,240:504-526.
[23] PAWAR V K,MEHER J G,SINGH Y,et al.Targeting of gastrointestinal tract for amended delivery of proteins/peptides therapeutics:strategies and industrial perspectives[J].J Control Release,2014,196:168-183.
[24] KRISTENSEN M,NIELSEN H M.Cell-penetrating peptides as carriers for oral delivery of biopharmaceuticals[J].Basic Clin Pharmacol Toxicol,2016,118(2):99-106.
[25] WANG F,ZHANG D,ZHANG Q,et al.Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel-polymer micelles to overcome multi-drug resistance[J].Biomaterials,2011,32(35):9444-9456.
[26] HULS M,RUSSEL F G M,MASEREEUW R.The role of ABC transporters in tissue defense and organ regeneration[J].J Pharmacol Exp Ther,2008,328(1):3-9.
[27] GAO L,WANG X,MA J,et al.Evaluation of TPGS-modified thermo-sensitive Pluronic PF127 hydrogel as a potential carrier to reverse the resistance of P-gp-overexpressing SMMC-7721 cell lines[J].Colloids Surfaces B,2016,140:307-316.
[28] WANG J,SUN J,CHEN Q,et al.Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance[J].Biomaterials,2012,33(28):6877-6888.
[29] WAN C P,LETCHFORD K,JACKSON J K,et al.The combined use of paclitaxel-loaded nanoparticles with a low-molecular-weight copolymer inhibitor of P-glycoprotein to overcome drug resistance[J].Int J Nanomed,2013,8:379-391.
[30] 徐巍,牟燕,李宏建.聚合物胶束提高难溶性药物生物利用度的研究进展[J].中国药房,2015(13):1847-1850.
[31] HOU J,SUN E,ZHANG Z H,et al.Improved oral absorption and anti-lung cancer activity of paclitaxel-loaded mixed micelles[J].Drug Deliv,2017,24(1):261-269.
[32] CHEN M C,MI F L,LIAO Z X,et al.Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules[J].Adv Drug Deliv Rev,2013,65(6):865-879.
[33] 管庆霞,高远,李永吉.pH敏感性材料在口服给药系统中的研究[J].哈尔滨商业大学学报(自然科学版),2013,29(2):133-137.
[34] LI J,HUANG P,CHANG L,et al.Tumor targeting and pH-responsive polyelectrolyte complex nanoparticles based on hyaluronic acid-paclitaxel conjugates and chitosan for oral delivery of paclitaxel[J].Macromol Res,2013,21(12):1331-1337.
[35] WANG Q,LI C,REN T,et al.Poly(vinyl methyl ether/maleic anhydride)-doped PEG-PLA nanoparticles for oral paclitaxel delivery to improve bioadhesive efficiency[J].Mol Pharm,2017,14(10):3598-3608.
[36] SUH J W,LEE J S,KO S,et al.Preparation and characterization of mucoadhesive buccal nanoparticles using chitosan and dextran sulfate[J].J Agric Food Chem,2016,64(26):5384-5388.
[37] SILVA D S,ALMEIDA A,PREZOTTI F G,et al.Self-aggregates of 3,6-O,O’-dimyristoylchitosan derivative are effective in enhancing the solubility and intestinal permeability of camptothecin[J].Carbohydr Polym,2017,177:178-186.
[38] LV P P,WEI W,YUE H,et al.Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration[J].Biomacromolecules,2011,12(12):4230-4239.
[39] WERLE M,BERNKOP-SCHNURCH A.Thiolated chitosans:useful excipients for oral drug delivery[J].J Pharm Pharmacol,2008,60(3):273-281.
[40] SIDDHARTH S,NAYAK A,NAYAK D,et al.Chitosan-dextran sulfate coated doxorubicin loaded PLGA-PVA-nanoparticles caused apoptosis in doxorubicin resistance breast cancer cells through induction of DNA damage[J].Sci Rep,2017,7(1):2143.
[41] LIAN H,ZHANG T,SUN J,et al.Enhanced oral delivery of paclitaxel using acetylcysteine functionalized chitosan-vitamin E succinate nanomicelles based on a mucus bioadhesion and penetration mechanism[J].Mol Pharm,2013,10(9):3447-3458.
[42] HUO M,FU Y,LIU Y,et al.N-mercapto acetyl-N’-octyl-O,N″-glycol chitosan as an efficiency oral delivery system of paclitaxel[J].Carbohydr Polym,2018,181:477-488.[43] NGUYEN T X,HUANG L,GAUTHIER M,et al.Recent advances in liposome surface modification for oral drug delivery[J].Nanomedicine,2016,11(9):1169-1185.
[44] JAIN S,KUMAR D,SWARNAKAR N K,et al.Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel[J].Biomaterials,2012,33(28):6758-6768.
[45] WANG Q,WEI Q,YANG Q.A novel formulation of [6] -gingerol:proliposomes with enhanced oral bioavailability and antitumor effect[J].Int J Pharm,2018,535(1/2):308-315.
[46] WU J,LIU Q,LEE R J.A folate receptor-targeted liposomal formulation for paclitaxel[J].Int J Pharm,2006,316(1/2):148-153.
[47] TAKEUCHI H,YAMAMOTO H,NIWA T,et al.Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes[J].Pharm Res,1996,13(6):896-901.
[48] YANG M,LAI S K,WANG Y Y,et al.Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus[J].Angew Chem Int Ed,2011,50(11):2597-2600.
[49] CHEN D,XIA D,LI X,et al.Comparative study of Pluronic F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats[J].Int J Pharm,2013,449(1/2):1-9.
[50] DIAB R,CANILHO N,PAVEL I A.,et al.Silica-based systems for oral delivery of drugs,macromolecules and cells[J].Adv Colloid Interface Sci,2017,249:346-362.
[51] TIAN B,LIU S,WU S,et al.pH-responsive poly(acrylic acid)-gated mesoporous silica and its application in oral colon targeted drug delivery for doxorubicin[J].Colloids Surfaces B,2017,154:287-296.
[52] WANG Y,ZHAO Y,CUI Y,et al.Overcoming multiple gastrointestinal barriers by bilayer modified hollow mesoporous silica nanocarriers[J].Acta Biomater,2018,65:405-416.
[53] GHOLIPOURMALEKABADI M,MOBARAKI M,GHAFFARI M,et al.Targeted drug delivery based on gold nanoparticle derivatives[J].Curr Pharm Design,2017,23(20):2918-2929.
[54] DHESINGH R S,THAMBIRAJ S,HEMA S.An overview on applications of gold nanoparticle for early diagnosis and targeted drug delivery to prostate cancer[J].Recent Patents Nanotech,2017,12(2):110-131.
[55] CHEN Y,XU M,GUO Y,et al.Targeted chimera delivery to ovarian cancer cells by heterogeneous gold magnetic nanoparticle[J].Nanotechnology,2017,28(2):025101.
[56] KANG S H,REVURI V,LEE S J,et al.Oral siRNA delivery to treat colorectal liver metastases[J].ACS Nano,2017,11(10):10417-10429.

备注/Memo

备注/Memo:
收稿日期:2018-04-23修回日期:2018-07-23
基金项目:国家自然科学基金(81102397、81503261)
作者简介:于艳芳(1974—),女,山东文登人,博士,工程师,研究方向:新型给药系统; 霍美蓉(联系人),教授,E-mail:huomeirongcpu@163.com
引文格式:于艳芳,刘艳红,霍美蓉.纳米递送载体在口服抗肿瘤药物给药系统中的应用[J].生物加工过程,2018,16(5):64-70.
YU Yanfang,LIU Yanhong,HUO Meirong.Application of nanocarriers for oral delivery of anticancer drugs [J].Chin J Bioprocess Eng,2018,16(5):64-70..
更新日期/Last Update: 2018-09-30